Connect with us
Federal regulators approved Johnson & Johnson’s (NYSE: JNJ) nasal spray Spravato as the first stand-alone therapy for adults with treatment-resistant depression. The Food and Drug Administration’s...
Psychedelic drug company Mind Medicine Inc. (MindMed) (NASDAQ: MNMD) published its 2025 Investor Presentation this week with more detail on its plans than the company’s 2024...
Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) announced it would be bought by Graft Polymer (UK) PLC with Graft acquiring all of the company’s shares...
Relmada Therapeutics Inc. (Nasdaq: RLMD) will halt its Phase 3 studies of depression treatment REL-1017 following a data monitoring committee evaluation, sending the company searching for...
The Journal of American Medical Association (JAMA) published a report this week noting the increase in diversions of the drug ketamine. The report was authored by...
The Department of Veterans Affairs will fund a $1.5 million study of MDMA-assisted psychotherapy for veterans with PTSD and alcohol use disorder, marking its first foray...
Canadian psychedelics company Red Light Holland Corp. (CSE: TRIP) (OTCQB: TRUFF) cut its quarterly losses and grew sales as its mushroom and truffle business expanded across...
Psyence Biomedical Ltd. (Nasdaq: PBM) will implement a 1-for-75 share consolidation next week as the psychedelics company works to maintain its Nasdaq listing, the company said...
Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) agreed to sell its five Utah clinics to psychiatric care provider Stella. The deal will also create a data-sharing...
Enveric Biosciences Inc. (NASDAQ: ENVB) reported its financial results for the third quarter of 2024 and provided a corporate update yesterday. Enveric said it made “important progress”...
